Zydus Lifesciences wraps up enrollment for Phase II ALS trial of Usnoflast
Zydus Lifesciences, a renowned global pharmaceutical company, has achieved a significant milestone by completing the enrollment for the Phase II clinical trial of its novel ... Read More
Gland Pharma gains FDA approval for Edaravone Injection, set to treat ALS
Gland Pharma Limited, a prominent player in the generic injectable-focused pharmaceutical industry, has received approval from the United States Food and Drug Administration (USFDA) for ... Read More
Amylyx Pharmaceuticals’ AMX0035 misses primary and secondary endpoints in ALS study
Cambridge, Massachusetts-based Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), a key player in the pharmaceutical industry, announced today the top-line results of the PHOENIX study, a critical ... Read More